Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies ... in those drugs, semaglutide, is no ...

Compounding pharmacies will no longer be allowed to create semaglutide injections, a generic and cheaper version of Ozempic and Wegovy. This comes after a judge rejected a bid by these pharmacies to ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Wegovy, a year ago. CEO Andrew Dudum said he believes the company’s partnership with Novo Nordisk will serve as ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

When the FDA declared the shortage resolved for semaglutide, the main pharmaceutical ingredient in Wegovy and Ozempic, the agency gave 503B facilities until May 22 to stop making compounded versions.

The FDA may begin enforcement actions against pharmacies compounding ... the shortage of Wegovy and Ozempic, no patient should have to be exposed to unsafe, inauthentic ‘semaglutide’ drugs ...

Novo Nordisk scored a huge legal victory that largely restricts compounding ... semaglutide, is no longer in shorter in the U.S. Patients flocked to the cheaper copycats when Ozempic and Wegovy ...